Journal
BLOOD
Volume 118, Issue 25, Pages E184-E191Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-10-311464
Keywords
-
Categories
Funding
- American Heart Association [0970178N]
- National Institutes of Health [DE019191, HL095722, HL097172]
- Massachusetts Institute of Technology
- Kauffman Foundation
- Human Frontier Science Program (Postdoctoral Fellowship)
Ask authors/readers for more resources
One of the greatest challenges in cell therapy is to minimally invasively deliver a large quantity of viable cells to a tissue of interest with high engraftment efficiency. Low and inefficient homing of systemically delivered mesenchymal stem cells (MSCs), for example, is thought to be a major limitation of existing MSCbased therapeutic approaches, caused predominantly by inadequate expression of cell surface adhesion receptors. Using a platform approach that preserves the MSC phenotype and does not require genetic manipulation, we modified the surface of MSCs with a nanometer-scale polymer construct containing sialyl Lewis(x) (sLe(x)) that is found on the surface of leukocytes and mediates cell rolling within inflamed tissue. The sLex engineered MSCs exhibited a robust rolling response on inflamed endothelium in vivo and homed to inflamed tissue with higher efficiency compared with native MSCs. The modular approach described herein offers a simple method to potentially target any cell type to specific tissues via the circulation. (Blood. 2011; 118(25): e184-e191)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available